CIK 0001826457 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Monte Rosa Therapeutics, Inc.
Sign in to watch- Ticker
- GLUE
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-949-2643
- Business address
- 321 HARRISON AVENUE, SUITE 900, BOSTON, MA, 02118
- Former names
- Monte Rosa Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $137
- in 1 filing
Net −$137. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 35 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-06-03 | Dunn Edmund Principal Accounting Officer | Sale | −1,207 | $4.04 | $5K | 15,554 |
| 2024-06-03 | Nickson Philip Chief Business & Legal Officer | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2024-06-03 | Townson Sharon Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2024-06-03 | Champoux Jennifer Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2024-01-02 | Nickson Philip General Counsel | Grant or award · Stock Option (Right to Buy) | +109,000 | 109,000 | ||
| 2024-01-02 | Wallace Owen B. Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +119,000 | 119,000 | ||
| 2024-01-02 | Warmuth Markus President & CEO | Grant or award · Stock Option (Right to Buy) | +346,000 | 346,000 | ||
| 2024-01-02 | Jones Jullian G Chief Business Officer | Grant or award · Stock Option (Right to Buy) | +79,000 | 79,000 | ||
| 2024-01-02 | Dunn Edmund Principal Accounting Officer | Grant or award · Stock Option (Right to Buy) | +25,000 | 25,000 | ||
| 2024-01-02 | Dunn Edmund Principal Accounting Officer | Grant or award · Stock Option (Right to Buy) | +35,900 | 35,900 | ||
| 2024-01-02 | Janku Filip Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +121,000 | 121,000 | ||
| 2023-07-25 | Manning Anthony M. Director | Grant or award · Stock Option (Right to Buy) | +41,000 | 41,000 | ||
| 2023-06-14 | Behbahani Ali Director | Grant or award · Stock Option (Right to Buy) | +20,500 | 20,500 | ||
| 2023-06-14 | Skvarka Jan Director | Grant or award · Stock Option (Right to Buy) | +20,500 | 20,500 | ||
| 2023-06-14 | Siu Christine Director | Grant or award · Stock Option (Right to Buy) | +20,500 | 20,500 | ||
| 2023-06-14 | SCHIFF ANDREW N Director | Grant or award · Stock Option (Right to Buy) | +20,500 | 20,500 | ||
| 2023-06-14 | Mayweg Alexander Director | Grant or award · Stock Option (Right to Buy) | +20,500 | 20,500 | ||
| 2023-06-14 | Blackwell Kimberly Director | Grant or award · Stock Option (Right to Buy) | +20,500 | 20,500 | ||
| 2023-03-30 | Skvarka Jan Director | Grant or award · Stock Option (Right to Buy) | +41,000 | 41,000 | ||
| 2023-01-03 | Wallace Owen B. Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +135,000 | 135,000 |
Page 8 of 9 · 174 trades